A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant brea... by Esmeralda García-Torralba, Esmeralda García-Torralba, Esmeralda García-Torralba, Esther Navarro Manzano, Esther Navarro Manzano, Gines Luengo-Gil, Gines Luengo-Gil, Gines Luengo-Gil, Pilar De la Morena Barrio, Pilar De la Morena Barrio, Pilar De la Morena Barrio, Asunción Chaves Benito, Miguel Pérez-Ramos, Beatriz Álvarez-Abril, Beatriz Álvarez-Abril, Beatriz Álvarez-Abril, Alejandra Ivars Rubio, Alejandra Ivars Rubio, Alejandra Ivars Rubio, Elisa García-Garre, Elisa García-Garre, Elisa García-Garre, Francisco Ayala de la Peña, Francisco Ayala de la Peña, Francisco Ayala de la Peña, Elena García-Martínez, Elena García-Martínez, Elena García-Martínez, Elena García-Martínez

Get full text

Clinical Meaning of Stromal Tumor Infiltrating Lymphocytes (sTIL) in Early Luminal B Breast Cancer by Esmeralda García-Torralba, Miguel Pérez Ramos, Alejandra Ivars Rubio, Esther Navarro-Manzano, Noel Blaya Boluda, Pilar de la Morena Barrio, Elisa García-Garre, Francisco Martínez Díaz, Asunción Chaves-Benito, Elena García-Martínez, Francisco Ayala de la Peña

Get full text

Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvan... by Silvia Antolín Novoa, Santiago Escrivá-de-Romaní, Pablo Tolosa Ortega, Lucía Oliva Fernández, Rafael López López, Ana López González, Pilar de la Morena Barrio, Isabel Echavarria Díaz-Guardamino, José Enrique Alés Martinez, Zita Garate, Lucia González-Cortijo

Get full text